By Dominic Chopping
Bavarian Nordic AS said Monday that its Imvanex smallpox vaccine has been approved for use against monkeypox by the European Commission.
The approval follows last week’s positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use and is valid in all European Union member states as well as in Iceland, Liechtenstein and Norway, it said.
The World Health Organization declared monkeypox a public health emergency of international concern over the weekend.
The company’s Imvanex vaccine is approved for use against monkeypox by the U.S. and Canada, and Bavarian Nordic has signed several contracts with undisclosed countries for the vaccine, resulting in the company raising its full-year guidance six times in two months.
Shares have more than doubled since the monkeypox outbreak began in mid-May.
Write to Dominic Chopping at [email protected]
